Clene Inc. (NASDAQ:CLNNW) Sees Significant Increase in Short Interest

Clene Inc. (NASDAQ:CLNNW) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 6,300 shares, a growth of 18.9% from the August 15th total of 5,300 shares. Based on an average trading volume of 8,600 shares, the days-to-cover ratio is presently 0.7 days.

Clene Stock Performance

Shares of CLNNW stock traded up $0.01 during trading on Friday, hitting $0.05. The company’s stock had a trading volume of 313 shares, compared to its average volume of 10,735. The business has a fifty day moving average of $0.04 and a 200-day moving average of $0.05. Clene has a 52 week low of $0.02 and a 52 week high of $0.10.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.